<DOC>
	<DOCNO>NCT00003803</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether chemotherapy follow radiation therapy effective chemotherapy give radiation therapy non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness two different regimen chemotherapy radiation therapy treat patient unresectable stage I , stage II , stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Radiation Therapy Treating Patients With Stage I , Stage II , Stage III Non-small Cell Lung Cancer That Can Be Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival , disease-free survival , local control , pattern recurrence patient unresectable stage I , II , low-volume stage III non-small lung cancer treat high-dose radiotherapy either preceded induction chemotherapy gemcitabine cisplatin combine daily cisplatin . - Compare acute late toxic effect regimens patient . - Determine quality life patient . OUTLINE : This randomize , multicenter study . Patients stratify accord performance status ( 0 vs 1 ) , TNM stage , participate center . Patients randomize one two treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute day 1 8 cisplatin IV 3-6 hour day 2 . Treatment repeat 21 day later . Patients undergo high-dose accelerate conformal radiotherapy begin week 9 ( day 57 ) , 5 day week , 24 fraction , use concurrent boost technique 66 Gy . - Arm II : Patients receive low-dose cisplatin IV follow 1-2 hour later high-dose accelerate conformal radiotherapy . Treatment continue daily , 5 day week , 24 fraction , use concurrent boost technique 66 Gy . Quality life assess treatment week 9-11 , 19 , 27 , 35 . Patients follow 3 week , 6-7 week , every 8 week thereafter . PROJECTED ACCRUAL : A total 418 patient ( 209 per arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Stage I , II , III ( T14 , N03 , M0 ) No metastases supraclavicular , contralateral hilar , contralateral scalene lymph node Medically inoperable unresectable No pleural pericardial effusion ( except repeat negative cytology ) PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 6.8 g/dL No hemoptysis cause decrease hemoglobin 1 g/dL within 24 hour Hepatic : Not specify Renal : Creatinine great 1.25 time normal OR Creatinine clearance great 70 mL/min Cardiovascular : No evidence heart failure No myocardial infarction within past 6 month No superior vena cava syndrome Pulmonary : FEV1 least 1 L No preexist fibrotic lung disease No postobstructive pneumonia prevent exact delineation tumor volume Diffusion capacity least 60 % Other : No weight loss 10 % past 3 month No uncontrolled infection No serious medical risk factor involve major organ system would preclude adherence study treatment schedule PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy chest Maximum length esophagus receive 40 Gy great 18 cm Maximum length esophagus receive 66 Gy great 12 cm Must limit spinal cord dose maximum 50 Gy Must able exclude 25 % heart boost volume Surgery : Not specify Other : No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage III non-small cell lung cancer</keyword>
</DOC>